Ipsen Presents New Data on Neurological Disorders at TOXINS 2026 Congress
The biopharmaceutical group unveiled 14 scientific communications on various movement disorders at the Madrid congress, according to the statement released on Tuesday.
Interim Analysis of the EPITOME Epidemiological Study
The interim analysis of the EPITOME epidemiological study, presented at the congress, showed that 45.7% of stroke survivors with paresis develop spasticity within a year following the event, the company indicates. This rate is higher than the 39.5% observed in previous data. The multicenter study follows adults aged 18 to 85 years after their first stroke and notably evaluates a monitoring questionnaire allowing remote patient follow-up. According to the group, this approach aims to facilitate early detection of spasticity, a condition that can go unnoticed and delay treatment.
Real-World Data Highlighted by Ipsen
Real-world data cited by Ipsen reveal that currently less than 1% of stroke survivors receive type A botulinum toxin treatment in routine practice. This observation highlights a significant gap between therapeutic needs and the reality of care provided, the laboratory emphasizes. The communications presented in Madrid also cover other neurological pathologies treated with Dysport, the group's abobotulinumtoxinA-based product, including cervical dystonia, blepharospasm, and various movement disorders. Sandra Silvestri, Ipsen's medical director, stated that the EPITOME study aims to establish standardized monitoring to ensure patients receive appropriate care.
Overview of the 14 Presentations
The set of 14 presentations predominantly includes poster communications and one oral presentation, focusing on the efficacy and safety of the treatment in various indications. Several studies analyze the real-life use of botulinum toxin in post-stroke spasticity, parkinsonian syndromes, and hyperkinetic movement disorders, including data from French and Swedish sources. One communication also addresses the methodology of the phase 3 BEOND clinical trials evaluating abobotulinumtoxinA in the prevention of migraines. Dysport is currently authorized for marketing in about 90 countries, with over 30 years of clinical experience and more than 18 million patient-years of experience, according to information provided by the group.
